MENT (Trestolone)
19-Nor Anabolic Steroid | Experimental TRT Alternative
Community Research
Join others researching MENT — share findings, ask questions, and learn from real experiences
MENT (7-alpha-methyl-19-nortestosterone), also known as trestolone, is an experimental synthetic anabolic-androgenic steroid that belongs to the 19-nor (nandrolone) family. It was originally developed by the Population Council as a potential male hormonal contraceptive and androgen replacement therapy. MENT is estimated to be roughly 10 times more potent than testosterone on a milligram-per-milligram basis, which allows for effective use at very low doses. Unlike nandrolone, MENT does not cause the characteristic sexual dysfunction ('deca dick') associated with other 19-nor compounds, because it maintains sufficient androgenic activity in the central nervous system and sexual tissues. This property has generated significant interest in MENT as a potential standalone replacement for testosterone -- a compound that could serve as both the anabolic and androgenic base in hormone replacement protocols. MENT aromatizes, but its aromatization product is 7-alpha-methyl-estradiol rather than standard estradiol. This methylated estrogen behaves differently from estradiol in some respects, and aromatase inhibitors like anastrozole have reduced efficacy against it. Estrogen management on MENT is therefore considered more challenging than with testosterone. The acetate ester is the most widely available formulation and has an extremely short half-life of approximately 40 minutes, necessitating daily or twice-daily injections for stable blood levels. Research into longer-acting esters and delivery systems (including subdermal implants) is ongoing. MENT remains an investigational compound with no current FDA approval, though Phase 2 clinical trials for male contraception have been conducted.
MENT binds to the androgen receptor with high affinity, estimated at roughly 10 times the potency of testosterone, driving robust activation of AR-dependent gene transcription pathways responsible for protein synthesis, nitrogen retention, and satellite cell proliferation in skeletal muscle. Its 7-alpha methyl group renders it resistant to 5-alpha reductase, meaning it is not converted to a reduced metabolite in androgen-sensitive tissues the way testosterone is converted to DHT or nandrolone is converted to DHN. MENT itself acts directly on androgen receptors throughout the body, including the brain, prostate, and sexual tissues, which is why it maintains libido and sexual function unlike nandrolone. MENT aromatizes via the aromatase enzyme, but the product is 7-alpha-methyl-estradiol rather than estradiol. This methylated estrogen retains estrogenic activity and binds to estrogen receptors, but conventional aromatase inhibitors (anastrozole, letrozole) have diminished ability to block its formation. The mechanism behind this reduced AI efficacy appears related to the 7-alpha methyl group altering the substrate's interaction with the aromatase active site. MENT powerfully suppresses the hypothalamic-pituitary-gonadal (HPG) axis, reducing LH and FSH to near-undetectable levels at relatively low doses. This profound gonadotropin suppression is the basis for its investigation as a male contraceptive, as it can reduce sperm production to azoospermia or severe oligospermia in most men. Despite its 19-nor classification, MENT does not appear to have the significant progestogenic activity that nandrolone exhibits, though some degree of progesterone receptor interaction has been reported in preclinical studies.
Molecular Data
Research Indications
MENT is being investigated as an alternative to testosterone for androgen replacement. Its high potency allows for low-volume injections, and unlike nandrolone it maintains sexual function without requiring a concurrent testosterone base. Subdermal implant formulations have been studied to provide sustained release over months, potentially offering a more convenient delivery method than testosterone injections.
MENT's primary clinical research focus. Phase 2 trials have demonstrated that MENT, alone or in combination with a progestin, can suppress spermatogenesis to azoospermia or severe oligospermia in the majority of men. The contraceptive effect is reversible upon discontinuation. MENT's advantage over testosterone-based contraceptive approaches is its greater potency and the fact that it does not require 5-alpha reduction for full androgenic activity.
MENT produces significant dose-dependent increases in lean body mass. Due to its potency being roughly 10 times that of testosterone, even low doses (5-10 mg/day) can produce anabolic effects comparable to moderate doses of testosterone. Higher doses (15-25 mg/day) produce substantial muscle growth but with increased side effect burden, particularly estrogenic effects.
Users consistently report rapid and significant strength increases on MENT, often noticeable within the first 1-2 weeks due to the fast-acting acetate ester. Strength gains appear to scale with dose and are accompanied by notable improvements in training recovery.
Unlike nandrolone and trenbolone (other 19-nor compounds), MENT maintains libido and erectile function because it acts directly on androgen receptors in the brain and sexual tissues without being reduced to a weaker metabolite. Many users report enhanced libido on MENT, particularly at lower doses before estrogenic side effects become prominent.
Dosing Protocols
MENT is most commonly available as trestolone acetate for intramuscular or subcutaneous injection. The acetate ester has an extremely short half-life of approximately 40 minutes, which means blood levels rise and fall rapidly. Daily injection is the absolute minimum frequency, and many users prefer twice-daily injections (morning and evening) to maintain more stable blood levels and reduce peak-related side effects. Longer-acting esters (trestolone decanoate, trestolone enanthate) have been discussed in research contexts but are not widely available. Subdermal implant formulations have been studied in clinical trials and could eventually provide sustained multi-month delivery.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| TRT Replacement - Low Dose | 5-10 mg/day | Daily (or split into 2 injections per day) | Intramuscular or subcutaneous |
| Moderate Anabolic Protocol | 10-15 mg/day | Split into 2 injections per day | Intramuscular or subcutaneous |
| Higher Dose - Advanced | 15-25 mg/day | Split into 2 injections per day | Intramuscular or subcutaneous |
Reconstitution Instructions
- MENT acetate vial (typically 50-100 mg/mL in MCT or carrier oil)
- Insulin syringes (0.5 mL or 1 mL with 27-31 gauge needle) for subcutaneous injection
- Alternatively: 1 mL syringes with 25-27 gauge needle for intramuscular injection
- Alcohol swabs
- Sharps container
- 1 Wash hands thoroughly and prepare a clean work surface
- 2 Wipe vial stopper with alcohol swab and allow to dry
- 3 Draw the prescribed dose into an insulin syringe (volumes are typically very small, 0.05-0.25 mL)
- 4 Clean injection site with alcohol swab
- 5 For subcutaneous: pinch skin at abdomen or love handle area, insert needle at 45-degree angle, inject slowly
- 6 For intramuscular: insert needle at 90-degree angle into deltoid, ventrogluteal, or vastus lateralis
- 7 Withdraw needle and apply gentle pressure with gauze
- 8 Dispose of needle in sharps container
- 9 Repeat daily or twice daily as per protocol
Interactions
What to Expect
Side Effects & Safety
Common Side Effects
- Estrogen management difficulty -- 7-alpha-methyl-estradiol is harder to control with conventional aromatase inhibitors
- Water retention and bloating, particularly at doses above 10 mg/day
- Elevated blood pressure, often linked to water retention and estrogenic load
- Mood changes including irritability, emotional sensitivity, or anxiety (frequently estrogen-related)
- Profoundly suppressive of the HPG axis -- LH and FSH driven to near-zero even at low doses
- Injection frequency burden (daily or twice-daily with acetate ester)
- Mild acne and oily skin
- Increased appetite
Stop Signs - Discontinue if:
- Severe chest pain, tightness, or pressure
- Sudden shortness of breath or difficulty breathing at rest
- Swelling, warmth, or pain in one leg (potential deep vein thrombosis)
- Severe or persistent headaches with visual disturbances
- Rapid or significant gynecomastia progression that does not respond to AI adjustment
- Signs of stroke: sudden numbness, confusion, trouble speaking, loss of coordination
- Persistent severe depression or suicidal ideation
- Blood pressure consistently above 160/100 despite management efforts
Contraindications
- Prostate cancer (active or history of hormone-sensitive prostate cancer)
- Breast cancer in males or females
- Pregnancy or potential for pregnancy
- Severe hepatic impairment
- Polycythemia (hematocrit above 54% at baseline)
- Uncontrolled hypertension or severe cardiovascular disease
- Uncontrolled heart failure
- Known hypersensitivity to trestolone or any formulation components
Quality Checklist
Good Signs
- Clear, pale yellow to colorless oil with no visible particles or cloudiness
- Proper labeling with concentration (typically 50 or 100 mg/mL), ester type (acetate), and expiration date
- Concentration consistent with labeled amount (MENT acetate is typically 50-100 mg/mL)
- Intact rubber stopper with no signs of prior puncture
- Oil draws smoothly with appropriate viscosity
- Third-party lab testing documentation available
Warning Signs
- Underground lab product without independent verification or batch testing
- Concentration claims above 100 mg/mL (MENT acetate has solubility limitations at higher concentrations)
- Vial label with spelling errors, misaligned printing, or unprofessional appearance
- Oil appears slightly darker than expected but is otherwise clear
- No documentation of carrier oil type
Bad Signs
- Cloudy, discolored, or particulate-containing solution (contamination risk)
- Crashed product (crystallized steroid visible in vial)
- Broken or missing tamper-evident seal on vial
- No labeling, incorrect labeling, or missing expiration date
- Pain, redness, or swelling at injection site lasting more than 72 hours (potential infection or abscess)
- Product sourced without any testing or third-party verification
References
- 7 alpha-methyl-19-nortestosterone (MENT): the optimal androgen for male contraceptionSundaram, K., Kumar, N., Monder, C., Bardin, C.W.Annals of Medicine (1993)
Foundational paper characterizing MENT as a candidate male contraceptive. Demonstrated that MENT is approximately 10 times more potent than testosterone for gonadotropin suppression and does not undergo 5-alpha reduction, providing the rationale for its development as a hormonal contraceptive.
- 7alpha-methyl-19-nortestosterone (MENT): the optimal androgen for male contraception and replacement therapyAnderson, R.A., Wu, F.C.International Journal of Andrology (2002)
Reviewed the pharmacological profile of MENT as both a contraceptive and androgen replacement agent. Confirmed its high potency, resistance to 5-alpha reductase, ability to maintain sexual function, and robust HPG axis suppression. Discussed subdermal implant formulations for sustained delivery.
- Comparison of the pharmacokinetics of subcutaneous and intramuscular administration of 7alpha-methyl-19-nortestosterone (MENT) in healthy menvon Eckardstein, S., Noe, G., Brache, V., et al.Contraception (2002)
Clinical pharmacokinetic study comparing subcutaneous and intramuscular delivery of MENT acetate. Found rapid absorption and short half-life by both routes, with peak blood levels within 30-60 minutes. Provided the clinical basis for dosing frequency recommendations.
- 7alpha-methyl-19-nortestosterone acetate (MENT Ac) combined with etonogestrel implant suppresses spermatogenesisWalton, M.J., Kumar, N., Baird, D.T., et al.Journal of Clinical Endocrinology and Metabolism (2007)
Phase 2 clinical trial demonstrating that MENT acetate subdermal implants combined with etonogestrel effectively suppressed spermatogenesis in healthy men. The majority of participants achieved azoospermia or severe oligospermia, supporting MENT's potential as a reversible male contraceptive.
- Hormonal male contraception: a proof of concept study with a novel combination of testosterone undecanoate and trestolone acetate (MENT)Surampudi, P., Page, S.T., Swerdloff, R.S., et al.Fertility and Sterility (2014)
Proof-of-concept study evaluating MENT acetate alongside testosterone undecanoate for male contraception. Demonstrated synergistic gonadotropin suppression and high rates of spermatogenic suppression, further validating the clinical development pathway for MENT-based contraceptive regimens.
Related Peptides
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.